Brief: Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial
22/06/2026 07:48
BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial June 22 (Reuters) - Guangzhou Innogen Pharmaceutical Group Co Ltd 2591.HK:
GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO - ON 17 JUNE, RECEIVES CHINA APPROVAL TO START PHASE IB TRIAL FOR EFSUBAGLUTIDE ALFA IN ADOLESCENT OBESITY
Further company coverage: 2591.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guangzhou Innogen Pharmaceutical
See all newsBrief: Guangzhou Innogen Pharmaceutical Appoints Jin Bai As Vice President
Brief: Guangzhou Innogen Pharmaceutical Says Xu Wenjie Resigns As Executive Director
Brief: Guangzhou Innogen Pharmaceutical Group Co's Founder, Senior Management Undertakes Six-Month Lock-Up
Brief: Guangzhou Innogen Pharmaceutical Announces Intention To Conduct On-Market H Share Repurchase
Brief: GUANGZHOU INNOGEN PHARMACEUTICAL Posts HY LOSS Of RMB115.5 MLN